Promentis closes $26M round and enters clinic; PellePharma gets breakthrough/orphan status; Shire appoints Dittrich as CFO
→ Milwaukee-based Promentis Pharmaceuticals has closed the final tranche of its previously-announced $26 million Series C …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
